Causes of development and progression of cardiorenal syndrome in heart failure patients. Prevention methods
https://doi.org/10.15829/1560-4071-2021-4160
Abstract
The review includes data on the pathogenesis of cardiorenal syndrome (CRS) in patients with heart failure (HF). Renal hypertension has been identified as an important cause of its development and progression. The mechanisms of its formation in patients with low cardiac output are considered. In this setting, renal vasoconstriction, due to neuroendocrine activation, and external parenchymal compression, due to increased intra-abdominal pressure, developed. Both mechanisms were responsible for the decreased glomerular filtration rate. Hypokalemia has often accompanied by CRS. Potassium deficiency aggravated the decrease in cardiac output and provoked arrhythmias. This increased renal hypertension. High doses of furosemide in the treatment of acute decompensated HF sometimes damaged the kidneys due to hypovolemia and hypokalemia. Such side effects of furosemide as a neuroendocrine activation with subsequent vasoconstriction and the development of endothelial dysfunction due to oxidative stress are considered. Two directions of prevention of nephrotoxic effects of the drug are proposed. The proposed prevention methods have shown encouraging results.
About the Authors
V. V. Davydov
Altai State Medical University
Russian Federation
Competing Interests: not
Russian Federation
Barnaul
Competing Interests: not
E. L. Arekhina
City Hospital
Russian Federation
Competing Interests: not
Russian Federation
Barnaul
Competing Interests: not
References
1. Palazzuoli A, Ruocco G. Heart-Kidney Interactions in Cardiorenal Syndrome Type 1. Adv Chronic Kidney Dis. 2018;25(5):408-17. doi:10.1053/j.ackd.2018.08.013.
2. Mareev YuV, Mareev VYu. Characteristics and treatment of hospitalized patients with CHF. Kardiologiia. 2017;57(S4):19-30. (In Russ.) doi:10.18087/cardio.2433.
3. Melenovsky V, Cervenka L, Viklicky O, et al. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome. Kidney Blood Press Res. 2018;43(5):1437-50. doi:10.1159/000493657.
4. Ostraga M, Gierlotka MJ, Stonka G, et al. Clinical characteristics, treatment, and prognosis of patients with ischemic and nonischemic acute severe heart failure: analysis of data from the COMMIT-AHF registry. Pol Arch Intern Med. 2017;127(5):328-35. doi:10.20452/pamw.3996.
5. Bishara B, Abu-Saleh N, Awad H, et al. Pneumoperitoneum aggravates renal function in cases of decompensated but not compensated experimental congestive heart failure: role of nitric oxide. J Urol. 2011;186(1):310-7. doi:10.1016/j.juro.2011.03.040.
6. Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J Am Soc Nephrol. 2011;22(4):615-21. doi:10.1016/ASN.2010121222.
7. Lazzarini V, Bettari L, Bugatti S, et al. Can we prevent or treat renal dysfunction in acute heart failure? Heart Fail Rev. 2012;17(2):291-303. doi:10.1007/s10741-011-9253-3.
8. Medvedeva EA, Shilyaeva NV, Iskhakov EN, Schukin YuV. Cardiorenal syndrome in chronic heart failure: pathogenesis, diagnostics, prognosis and opportunities for treatment. Russian Journal of Cardiology. 2017;(1):136-41. (In Russ.) doi:15829/1560-4071-2017-1-136-141.
9. Verbrugge FH, Martens P, Ameloot K, et al. Spironolactone to increase natriuresis in congestive heart failure with cardiorenal syndrome. Acta cardiologica. 2019;74(2):100-7. doi:10.1080/00015385.2018.1455947.
10. Reznik EV, Nikitin IG. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (Part I): definition, classification, pathogenesis, diagnosis, epidemiology. The Russian Archives of Internal Medicine. 2019;1(45):5-22. (In Russ.) doi:10.20514/2226-6704-2019-9-1-5-22.
11. Linhart C, Ulrich C, Greinert D, et al. Systemic inflammation in acute cardiorenal syndrome: an observational pilot study. ESC heart failure. 2018;5(5):920-30. doi:10.1007/s00392-017-1195-x.
12. Zannad F, Rossignol P. Cardiorenal Syndrome Revisited. Circulation. 2018;138(9):929-44. doi:10.1161/CIRCULATIONAHA.117.028814.
13. Virzi GM, Clementi A, Brocca A, et al. Epigenetics: a potential key mechanism involved in the pathogenesis of cardiorenal syndromes. J Nephrol. 2018;31(3):333-41. doi:10.1007/s40620-017-0425-7.
14. Di Lullo L, Reeves PB, Bellasi A, Ronco C. Cardiorenal Syndrome in Acute Kidney Injury. Semin Nephrol. 2019;39(1):31-40. doi:10.1016/j.semnephrol.2018.10.003.
15. Cunningham JW, Mehra MR. Hypokalemia in heart failure: A low or a high point? Eur J Prev Cardiol. 2020:2047487320914745. doi:10.1177/2047487320914745.
16. Straburzyriska-Migaj E. Treatment and prognosis in patients with acute severe heart failure: does etiology matter? Pol Arch Intern Med. 2017;127(5):308-9. doi:10.20452/pamw.4035.
17. Tazmini K, Frisk M, Lewalle A, et al. Hypokalemia Promotes Arrhythmia by Distinct Mechanisms in Atrial and Ventricular Myocytes. Circ Res. 2020;126(7):889-906. doi:10.1161/CIRCRESAHA.119.315641.
18. Fauvel JP, Gueyffier F, Thijs L, Ducher M. Combined effect of renal function and serum potassium level in sudden cardiac death in aging hypertensive subjects. Hypertens Res. 2018;41(6):469-74. doi:10.1038/s41440-018-0035-3.
19. Collins AJ, Pitt B, Reaven N, et al. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes. Am J Nephrol. 2017;46(3):213-21. doi:10.1159/000479802.
20. Zyryanov SK, Ushkalova EA. Comparative pharmacoeconomic analysis of medication for patients after acute decompensated heart failure. Russian Journal of Cardiology. 2020;25(1):3690. (In Russ.) doi:10.15829/1560-4071-2020-1-3690.
21. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society Of Cardiology. Russian scientific medical society of internal medicine guidelines for heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(S6):8-158. (In Russ.) doi:10.18087/cardio.2475.
22. Salleck D, John S. Cardiorenal syndrome. Med Klin Intensivmed Notfmed. 2019;114(5):439-43. doi:10.1007/s00063-017-0346-1.
23. Chitturi C, Novak JE. Diuretics in the Management of Cardiorenal Syndrome. Adv Chronic Kidney Dis. 2018;25(5):425-33. doi:10.1053/j.ackd.2018.08.008.
24. Costanzo MR. The Cardiorenal Syndrome in Heart Failure. Heart Fail Clin. 2020;16(1):81-97. doi:10.1016/j.hfc.2019.08.010.
25. Scurt FG, Kuczera T, Mertens PR, Chatzikyrkou C. The Cardiorenal Syndrome. Dtsch Med Wochenschr. 2019;144(13):910-6. doi:10.1055/a-0768-5899.
26. Rubinstein J, Sanford D. Treatment of Cardiorenal Syndrome. Cardiol Clin. 2019;37(3):267-73. doi:10.1016/j.ccl.2019.04.002.
27. Haynes R, Zhu D, Judge PK, et al. Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant. 2020;35(4):558-64. doi:10.1093/ndt/gfz058.
28. Molnar AO, Petrcich W, Weir MA, et al. The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease. Nephrol Dial Transplant. 2020;35(5):782-9. doi:10.1093/ndt/gfz167.
29. Wu X, Zhang W, Ren H, et al. Diuretics associated acute kidney injury: clinical and pathological analysis. Ren Fail. 2014;36(7):1051-5. doi:10.3109/0886022X.2014.917560.
30. Ikeda Y, Inomata T, Kida K, et al. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR. Kanagawa Aquaresis Investigators, Heart and vessels. 2019;34(3):442-51. doi:10.1007/s00380-018-1270-x.
31. Kurlykina NV, Seredenina EM, Orlova YaA. Use of loop diuretics in heart failure: Current aspects. Terapevticheskiy arkhiv. 2017;89(9):115-9. (In Russ.) doi:10.17116/terarkh2017899115-119.
32. Skogestad J, Aronsen JM. Hypokalemia-Induced Arrhythmias and Heart Failure: New Insights and Implications for Therapy. Front Physiol. 2018;9:1500. doi:10.3389/fphys.2018.01500.
33. Silbert BI, Ho KM, Lipman J, et al. Does Furosemide Increase Oxidative Stress in Acute Kidney Injury. Antioxid Redox Signal. 2017;26(5):221-6. doi:10.1089/ars.2016.6845.
34. Jujo K, Saito K, Ishida I, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC heart failure. 2016;3(3):177-88. doi:10.1002/ehf2.12088.
35. Heine GH, Rogacev KS. Pharmacologic treatment of heart failure with reduced ejection fraction in chronic kidney disease. Deutsche medizinische Wochenschrift (1946). 2019;144(24):1714-20. doi:10.1055/a-0887-0792.
36. Fabiano V, Carnovale C, Gentili M, et al. Enalapril Associated with Furosemide Induced Acute Kidney Injury in an Infant with Heart Failure. A Case Report, a Revision of the Literature and a Pharmacovigilance Database Analysis. Pharmacology. 2016;97(1-2):38-42. doi:10.1159/000441950.
37. Brandenburg V, Heine GH. The Cardiorenal Syndrome. Deutsche medizinische Wochenschrift. 2019;144(6):382-6. doi:10.1055/s-00000011.
38. Wettersten N, Maisel AS, Cruz DN. Toward Precision Medicine in the Cardiorenal Syndrome. Advances in chronic kidney disease. 2018;25(5):418-24. doi:10.1053/j.ackd.2018.08.017.
39. Tominaga N, Kida K, Inomata T, et al. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study. American journal of nephrology. 2017;46(5):417-26. doi:10.1159/000481995.
40. Nakano Y, Mizuno T, Niwa T, et al. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease. International heart journal. 2018;59(1):105-11. doi:10.1536/ihj.16-625.
41. Mariano F, Mella A, Vincenti M, Biancone L. Furosemide as a functional marker of acute kidney injury in ICU patients: a new role for an old drug. Journal of nephrology. J Nephrol. 2019;32(6):883-93. doi:10.1007/s40620-019-00614-1.
42. Jalaba S, Palermo J, Budavari AI. Which dosing of furosemide is better in acute decompensated heart failure? JAAPA. 2017;30(3):11-2. doi:10.1097/01.JAA.0000512242.43624.7a.
43. Bagshaw SM, Gibney RTN, Kruger P, et al. The effect of low-dose furosemide in critically ill patients with early acute kidney injury: A pilot randomized blinded controlled trial (the SPARK study). Journal of critical care. 2017;42:138-46. doi:10.1016/j.jcrc.2017.07.030.
44. Ni J, Jiang H, Wang F, et al. Effect of continuous furosemide infusion on outcome of acute kidney injury. Pakistan journal of medical sciences. 2019;35(3):754-7. doi:10.12669/pjms.35.3.1012.
45. Ng KT, Yap JLL. Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials. Anaesthesia. 2018;73(2):238-47. doi:10.1111/anae.14038.
Supplementary files
Review
For citations:
Davydov V.V., Arekhina E.L. Causes of development and progression of cardiorenal syndrome in heart failure patients. Prevention methods. Russian Journal of Cardiology. 2021;26(1):4160. (In Russ.) https://doi.org/10.15829/1560-4071-2021-4160
Views:
1282
Email this article 